Q2 2025 Nath Bio-Genes (I) Ltd Earnings Call Transcript
Key Points
- Nath Bio-Genes (India) Ltd (BOM:537291) reported a 7% year-over-year growth in top-line revenue for the first half of FY '25, reaching INR 276.07 crores.
- The company maintained a strong gross profit margin of 51%, indicating effective cost management and pricing strategies.
- Cotton and paddy segments showed significant growth, with cotton value increasing by 11% and paddy value by 5.48%, despite a drop in paddy volume.
- The company's credit rating was upgraded from BBB to BBB+, reflecting improved operational stability and financial health.
- Nath Bio-Genes is expanding its international presence, with successful advancements in its joint venture in Uzbekistan and trial marketing preparations in the Philippines.
- The paddy segment experienced a 4.5% drop in volume, which could indicate challenges in market demand or production issues.
- Despite overall growth, the company faces fluctuations in product volumes, which may impact future revenue stability.
- The company has a high inventory level of INR 160 crores at the end of Q2, which could tie up working capital and affect liquidity.
- The joint venture in Uzbekistan is still in its early stages, with no immediate revenue contribution, impacting consolidated profits.
- The company has not yet achieved significant sales in the Philippines, indicating potential delays in international market expansion.
Ladies and gentlemen, good day, and welcome to FY '25 Nath Bio-Genes' Limited conference call, hosted by Go India Advisors. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Deepika Sharma from Go India Advisors. Thank you, and over to you, ma'am.
Good evening, everyone, and welcome to the Q2 and H1 FY '25 earnings call of Nath Bio-Genes Limited. We have on the call Mr. Satish Kagliwal, Managing Director; Dr. Devinder Khurana; Mr. Amol Gupta, Chief Financial Officer; Mr. Harish Pandey, Business Lead. We must remind you that the discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risk that the company made. May I now request the management to take us through the financials and the business outlook, subsequent to which we will be opening the floor for Q&A. Thank you, and over to you, sir.
- ()
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
